A meta-analysis of ten trials in 2162 patients found that first-line EGFR-TKI plus chemotherapy improved progression-free and overall survival in ...
A narrative review finds that newer first-line combination regimens for advanced EGFR-mutated NSCLC extend survival but substantially increase toxicity and ...
A real-world cohort study of 327 patients with EGFR-mutated non-small cell lung cancer finds that continuing EGFR-TKI therapy plus anti-angiogenic ...
A new meta-analysis of 4,070 patients identifies EGFR L858R, poor performance status, and brain metastases as high-certency predictors of poorer ...
In a groundbreaking study that could reshape the therapeutic landscape for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), ...
